Zobrazeno 1 - 10
of 443
pro vyhledávání: '"Alexander M, Menzies"'
Autor:
Su Yin Lim, Ines Pires da Silva, Nurudeen A. Adegoke, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Jenny H. Lee, Helen Rizos
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-6 (2024)
Abstract Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, providing significant benefit to patients across various tumour types, including melanoma. However, around 40% of melanoma patients do not benefit from ICI treatment, and
Externí odkaz:
https://doaj.org/article/cb455c8e98424ccdb0dd49216c915acf
Autor:
Wei Yen Chan, Jenny H. Lee, Ashleigh Stewart, Russell J. Diefenbach, Maria Gonzalez, Alexander M. Menzies, Christian Blank, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-9 (2024)
Abstract Background Neoadjuvant therapy improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma. However, accurately predicting individual recurrence risk remains a significant challenge. We investigated circulating tumour
Externí odkaz:
https://doaj.org/article/180a7ebfa6044158ab23c831a636c694
Autor:
Xue Bai, MD, Aleigha R. Lawless, BS, Juliane A. Czapla, MS, Stefanie C. Gerstberger, MD, PhD, Benjamin C. Park, MD, Seungyeon Jung, BA, Rebecca Johnson, MN, Naoya Yamazaki, MD, PhD, Dai Ogata, MD, PhD, Yoshiyasu Umeda, MD, Caili Li, MB, Jun Guo, MD, PhD, Keith T. Flaherty, MD, Yasuhiro Nakamura, MD, PhD, Kenjiro Namikawa, MD, PhD, Georgina V. Long, MBBS, PhD, Alexander M. Menzies, MBBS, PhD, Douglas B. Johnson, MD, Ryan J. Sullivan, MD, Genevieve M. Boland, MD, PhD, Lu Si, MD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 105-114 (2024)
Background: Anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma. We hypothesized that there are discrepancies in survival, recurrence pattern and toxicity to adjuvant PD-1 between different ethnicities and m
Externí odkaz:
https://doaj.org/article/e27b5891bd9c4bf4a452fb755d884e7b
Autor:
Xinyu Bai, Grace H. Attrill, Tuba N. Gide, Peter M. Ferguson, Kazi J. Nahar, Ping Shang, Ismael A. Vergara, Umaimainthan Palendira, Ines Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, James S. Wilmott, Camelia Quek
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract The biological underpinnings of therapeutic resistance to immune checkpoint inhibitors (ICI) in adolescent and young adult (AYA) melanoma patients are incompletely understood. Here, we characterize the immunogenomic profile and spatial archi
Externí odkaz:
https://doaj.org/article/4e3968539ed44b5d8e921475912375ae
Autor:
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102564- (2024)
Externí odkaz:
https://doaj.org/article/377d8aad4882472db54c2cd4b6fbb9b1
Autor:
Domenico Mallardo, Rachel Woodford, Alexander M. Menzies, Lisa Zimmer, Andrew williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu, Michielin Olivier, Reinhard Dummer, Paul Lorigan, Dirk Schadendorf, Georgina V. Long, Ester Simeone, Paolo A. Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue f
Externí odkaz:
https://doaj.org/article/f9c9d70fb3694e94a830225a5081faab
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox, Thomas F. Gajewski, Jérôme Galon, Claus Garbe, Brian R. Gastman, Jeffrey E. Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S. Leidner, Roger S. Lo, Alexander M. Menzies, Olivier Michielin, Poulikos I. Poulikakos, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) o
Externí odkaz:
https://doaj.org/article/06bb97ac823040b3bb11134f118a0c11
Autor:
Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTLymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death receptor-1 (PD-1) significantly improved pro
Externí odkaz:
https://doaj.org/article/de51474a80d24f65bee9d63be6c7447f
Autor:
Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTImmune-related adverse events (irAEs) are side effects of immune checkpoint inhibitor therapy (ICI). While common irAEs have been well characterized, there are more limited data on rare immune related adverse events (RirAEs) due to low incide
Externí odkaz:
https://doaj.org/article/5fea4b8fffe544958754d98c4b9d90c4
Autor:
Yizhe Mao, Tuba N. Gide, Nurudeen A. Adegoke, Camelia Quek, Nigel Maher, Alison Potter, Ellis Patrick, Robyn P. M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Serigne N. Lo, Alexander M. Menzies, Inês Pires da Silva, Georgina V. Long, Richard A. Scolyer, James S. Wilmott
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background Gene expression profiling is increasingly being utilised as a diagnostic, prognostic and predictive tool for managing cancer patients. Single-sample scoring approach has been developed to alleviate instability of signature scores
Externí odkaz:
https://doaj.org/article/ef7110af153c44aabefb4fbcf176e3ad